Sam-A Pharmaceutical Co., Ltd. (009300) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Sam-A Pharmaceutical Co., Ltd. (009300:KRX), powered by AI.

Current Price
₩13,800
P/E Ratio
6.8
Market Cap
87.9B
Sector
Common Stock
What is the Sam-A Pharmaceutical Co., Ltd. stock price forecast?

Sam-A Pharmaceutical Co., Ltd. is currently trading at ₩13,800. View real-time AI analysis on Alpha Lenz.

What is Sam-A Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for Sam-A Pharmaceutical Co., Ltd. on Alpha Lenz.

What is Sam-A Pharmaceutical Co., Ltd.'s P/E ratio?

Sam-A Pharmaceutical Co., Ltd.'s P/E ratio is 6.8.

Sam-A Pharmaceutical Co., Ltd.

KRX · 009300
₩13,800+110(+0.80%)Market closedKRX regular session 09:00–15:30 KST
Ask about Sam-A Pharmaceutical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Sam-A Pharmaceutical Co., Ltd. trades at a P/E of 6.8 (undervalued) with modest ROE of 5.8%.

Ask for details

Company Overview

Sam-A Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical industry, renowned for its role in developing, manufacturing, and distributing a wide array of medicinal products. This company primarily focuses on the production of prescription drugs, over-the-counter (OTC) medications, and medical supplies, catering to various therapeutic areas. Its extensive portfolio is designed to address a multitude of health conditions, enhancing patient care and contributing to public health. Operating in South Korea, Sam-A Pharmaceutical leverages advanced research and development capabilities to innovate and introduce effective medical solutions. The company serves both domestic and international markets, highlighting its commitment to expanding its global footprint and increasing access to quality healthcare products. Sam-A Pharmaceutical plays a significant role in the healthcare sector, notably impacting areas such as chronic disease management and preventive medicine. By continually investing in cutting-edge technology and collaborating with global research entities, the firm has secured its position as a key contributor to the pharmaceutical industry's growth and resilience. Its market presence underscores the critical importance of pharmaceuticals in improving and sustaining health outcomes worldwide.

CEO허 준
SectorCommon Stock
IndustryCommon Stock
0

Company Statistics

FY 2025

Profile

₩87,906,000,000Market Cap
₩77,799,035,960Revenue
6.37MShares Out
0Employees

Margins

59.59%Gross
26.20%EBITDA
14.11%Operating
20.61%Pre-Tax
16.63%Net

Valuation

6.79P/E
0.39P/B
1.13EV/Sales
4.33EV/EBITDA
9.83P/FCF

Growth (CAGR)

-1.62%Rev 3Yr
7.71%Rev 5Yr
-15.59%Op Inc 3Yr
22.81%Op Inc 5Yr
2.80%Net Inc 3Yr
153.40%Net Inc 5Yr

Returns

5.22%ROA
5.78%ROE
6.65%ROIC

Financial Health

₩6,580,472,200Cash & Cash Equivalents
₩12,353,443,580Net Debt
8.30%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Sam-A Pharmaceutical Co., Ltd. (ticker: 009300) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $87.9B.

The current price is ₩13,800 with a P/E ratio of 6.79x and P/B of 0.39x.

ROE is 5.78% and operating margin is 14.11%. Annual revenue is $77.8B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Sam-A Pharmaceutical Co., Ltd. (009300) Stock Forecast 2026 ₩13,800 — Price, Financials & Analyst Targets | Alpha Lenz